Human pooled immunoglobulin in the treatment of chronic pain syndromes (Q39381451)

11 September 2017

title

Human pooled immunoglobulin in the treatment of chronic pain syndromes (English)

1 reference

11 September 2017

0 references

Andreas Goebel

1

1 reference

11 September 2017

Susanne Netal

series ordinal

2

1 reference

11 September 2017

Robert Schedel

series ordinal

3

1 reference

11 September 2017

Guenter Sprotte

series ordinal

4

1 reference

11 September 2017

publication date

1 June 2002

1 reference

11 September 2017

1 reference

11 September 2017

volume

3

1 reference

11 September 2017

issue

2

1 reference

11 September 2017

page(s)

119-127

1 reference

Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Adverse effects of intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Gabapentin in pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Screening of patients with complex regional pain syndrome for antecedent infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Etanercept reduces hyperalgesia in experimental painful neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Does a neuroimmune interaction contribute to the genesis of painful peripheral neuropathies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Different forms of LTD in the CA1 region of the hippocampus: role of age and stimulus protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Safety issues for plasma derivatives and benefit from NAT testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

Towards a mechanism-based classification of pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1526-4637.2002.02018.X

10.1046/J.1526-4637.2002.02018.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference